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Catechol-O-methyl transferase (COMT) is an enzyme involved in estrogen metabolism. Proteomic and immunoproteomic 
screens suggested COMT might be an immunogenic membrane antigen in human pancreatic cancer. The aim of this study was 
to investigate the dynamic expression of COMT in pancreatic ductal adenocarcinoma (PDAC) and noncancerous pancreatic 
tissue, and to determine the relationship between COMT expression and clinicopathologic parameters. COMT expression was 
analyzed by reverse transcription-polymerase chain reaction (RT-PCR) and western blot in five pancreatic cell lines and five 
pairs of PDAC and noncancerous pancreatic tissue. Immunohistochemistry was used to evaluate COMT expression in tissue 
microarrays and 20 cases of paraffin-embedded clinical specimens. The results indicated that COMT expression was detected 
in AsPC-1, BxPC-3, MIA PaCa-2, Capan-1 and SW1990 pancreatic cell lines, and in five pairs of PDAC and noncancerous 
pancreatic tissue, at the mRNA and protein levels. Immunohistochemistry analysis revealed that COMT expression was sig-
nificantly higher in PDAC than in nonmalignant pancreatic tissue. High expression of COMT significantly correlated to early 
T stages. Therefore, we conclude that COMT might serve as a potential biomarker for applied clinical pathology in PDAC. 
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Pancreatic cancer is the fourth leading cause of can-
cer-related mortality worldwide, and the death rate in fe-
males has increased in the last decade [1]. Radical surgical 
resection is one of the most important treatments to cure or 
prolong the survival of pancreatic cancer patients. However, 
only 10%–20% of all patients are suitable for potentially cu-
rative surgery [2,3]. Therefore, it is necessary to find tumor 
biomarkers for early diagnosis or tumor stage prediction. 
Currently the best marker available is carbohydrate antigen 
19-9, which has a sensitivity of approximately 80% and thus 
is not adequate for screening purposes, particularly for the 
diagnosis of localized, resectable pancreatic cancers [4,5]. 
In our previous studies [6,7], we screened membrane 
proteins from pancreatic cancer cell lines using two-dimen-      
sional electrophoresis, and performed immunoblotting with 
these proteins and serum IgG purified from clinically col-
lected sera of pancreatic cancer patients. Proteomic and 
immunoproteomic results suggested that catechol-O-methyl 
transferase (COMT) might be a candidate immunogenic 
membrane antigen in human pancreatic cancer. Based on 
these findings, we became interested in the expression and 
function of COMT in pancreatic cancer.  
The COMT gene is located at 22q11, and encodes two 
different mRNAs: a long membrane-bound COMT (MB-     
COMT) and a shorter soluble COMT (S-COMT) [8]. Pre-
748 Wu W M, et al.   Sci China Life Sci   September (2012) Vol.55 No.9 
vious studies demonstrated that COMT is overexpressed in 
colorectal cancer [9], and have focused on the effects of 
different gene variants of COMT on the risk of hor-
mone-dependent diseases, such as breast cancer [10–12], 
endometrial cancer [13], and gastric cancer [14]. However, 
the expression and function of COMT in pancreatic cancer 
has rarely been reported. Therefore, we aimed to investigate 
the expression of COMT in pancreatic cancer cell lines, 
human pancreatic ductal adenocarcinoma (PDAC) and 
nonmalignant pancreatic tissue, and to address the correla-
tion between COMT expression and the clinicopathologic 
parameters. 
1  Materials and methods 
1.1  Cell culture 
Human pancreatic cancer cell lines AsPC-1, BxPC-3, MIA 
PaCa-2, Capan-1 and SW1990 (all kind gifts from Professor 
Helmut Freiss, Technical University Munich, Germany) 
were maintained in 5% CO2 atmosphere at 37°C in Dul-
becco’s modified Eagle’s medium or RPMI 1640 medium 
(Hyclone, Thermo Fisher Scientific Inc., Waltham, MA, 
USA), supplemented with 10% fetal bovine serum (Hy-
clone). 
1.2  Clinical samples and tissue microarrays 
Five paired cases of PDAC and adjacent healthy pancreatic 
tissue were collected from the Department of General Sur-
gery of Peking Union Medical College Hospital (PUMCH). 
In addition, 20 paraffin-embedded tissue blocks of benign 
pancreatic-diseased tissue containing normal pancreatic 
tissue were obtained from the Pathology Department of 
PUMCH. Tissue microarrays with 80 paired sections of 
PDAC and adjacent para-carcinoma tissue were purchased 
from Shanghai Outdo Biotech Co. Ltd. (catalogue No. 
OD-CT-DgPan01-007). All of the human specimens in the 
study were approved by the ethics committee of PUMCH. 
1.3  Reverse transcription-polymerase chain reaction 
(RT-PCR) 
Total RNA was extracted using Trizol reagent (Invitrogen, 
Carlsbad, CA, USA) and cDNA was synthesized using an 
RT-PCR kit (Invitrogen) according to the manufacturer’s 
instructions. The COMT primers used were as follows: 5′- 
ATTGACACCTACTGCGAGCA-3′ and 5′-CCACATTCC- 
TCCAAGAGAAGC-3′. The internal control GAPDH pri-
mers were 5′-GGCTGCCATTTGCACTGGCAA-3′ and 5′- 
TGCCDTGAGTGGAGTCATACTG-3′. The PCR condi-
tions were as follows: pre-denaturing at 94°C for 2 min, 30 
cycles of denaturing at 94°C for 30 s, annealing at 60°C for 
30 s, and polymerization at 72°C for 30 s, then extension for 
5 min. The target bands were densitometrically analyzed 
using the UVISoft UVIBand Application V97.04 and 
FluorChem image analyzing software (Alpha Innotech, San 
Leandro, CA, USA), and the results were calculated as the 
ratio of the gray value relative to GAPDH. 
1.4  Western blotting 
Total protein was purified from pancreatic cancer cell lines 
and tissues, separated on 12% SDS-acrylamide gels, and 
electrotransferred to polyvinylidene fluoride membranes 
(Millipore, Billerica, MA, USA). After blocking, the mem-
branes were incubated overnight at 4°C with primary anti-
bodies against COMT (1:500 dilution; Santa Cruz Bio-
technology, Santa Cruz, CA, USA) and -actin (1:2000 
dilution; Santa Cruz), followed by incubation with horserad-
ish peroxidase (HRP)-conjugated anti-rabbit and anti-mouse 
secondary antibodies (1:2000 dilution; ZhongShan Golden-
Bridge Biotechnology, China) for 1 hour at room tempera-
ture. The blots were visualized with Immobilon™ Western 
(Millipore) and densitometrically analyzed using UVISoft 
UVIBand Application V97.04 and FluorChem (Alpha 
Innotech). The results were calculated as the ratio of the 
gray value relative to β-actin. 
1.5  Immunohistochemistry 
Tissue microarrays and 20 paraffin-embedded sections con-
taining normal pancreas specimens were dewaxed and re-
hydrated in xylene and graded alcohol, followed by citrate 
buffer (pH 6.0) retrieval using the high pressure method. 
After blocking peroxidase, the sections were incubated with 
anti-COMT primary antibody (1:800 dilution for tissue 
microarrays and 1:200 for slides) at 37°C for 2 h. Next, the 
sections were treated with an HRP polymer kit, Polink-1 
HRP Broad Bulk Kit (Golden Bridge International, Inc., 
Los Angeles, CA, USA) for signal amplification. Diamino-
benzidine was used as the chromogen and the sections were 
counterstained with hematoxylin. 
1.6  Determination of COMT score 
According to published methods [15], the staining intensity 
of COMT was classified as absent: 0; weak: 1; medium: 2; 
and strong: 3. The percentage of positive cells was catego-
rized as 0 (<5%), 1 (5%–25%), 2 (>25%–50%), 3 (>50%– 
75%), and 4 (>75%). By multiplying the value of the stain-
ing intensity by the categorized value of positive cells, a 
final immunohistochemical score was obtained.  
1.7  Statistical analysis 
Statistical analysis was performed using SPSS 13.0 software 
package (SPSS Inc., Chicago, IL, USA). Differences be-
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tween groups were evaluated by Chi-square or Fisher’s ex-
act tests (two-sided), and Mann-Whitney U-test. P-values of 
<0.05 were regarded as statistically significant.  
2  Results 
2.1  COMT expression in pancreatic cancer cell lines 
RT-PCR results showed that COMT was amplified as a 
fragment of 388 bp in all five pancreatic cancer cell lines 
(Figure 1A). The COMT protein was also detected in the 
five pancreatic cancer cell lines by western blotting analysis 
(Figure 1B). Two bands of 26 and 30 kD conformed respec-
tively to the molecular weights of the two subtypes of 
COMT proteins, S-COMT and MB-COMT.  
2.2  COMT expression in PDAC and noncancerous 
tissue 
Five paired samples of PDAC and adjacent normal pancre-
atic tissue were used for the analysis of COMT expression. 
RT-PCR revealed that in samples 2 and 3, COMT mRNA 
expression in PDAC was more than two-fold higher than in 
the adjacent healthy tissue, while in samples 1, 4 and 5, 
COMT mRNA expression in PDAC was slightly lower than 
in the adjacent healthy tissues (Figure 2A). In summary, 
there were no significant differences (P>0.05) between 
COMT mRNA expression in PDAC and that of paired ad-
jacent healthy tissue, as evaluated by the ratio of the gray 
value relative to GAPDH.  
Next, COMT protein expression in the above five paired 
samples was analyzed by western blotting. In line with the 
RT-PCR results, the expression level of COMT in these 
samples was not significantly different (P>0.05), as evalu- 
 
 
Figure 1  Expression of COMT in AsPC-1, BxPC-3, MIA PaCa-2, Ca-
pan-1 and SW1990 pancreatic cancer cell lines. A, Expression of COMT 
mRNA. GAPDH was used as an internal control. M, marker. B, Expression  
of COMT protein. -actin was used as an internal control. 
 
Figure 2  Expression of COMT in five paired clinical samples of PDAC 
and adjacent nonmalignant pancreatic tissue. A, Expression of COMT 
mRNA. GAPDH was used as an internal control. M, marker. B, Expression 
of COMT protein. -actin was used as an internal control. N, normal pan- 
creatic tissue; T, tumor. 
ated by the ratio of the gray value relative to -actin (Figure 
2B).  
2.3  Immunohistochemical analysis of COMT expres-
sion in PDAC and noncancerous tissue 
We further analyzed COMT protein expression in PDAC 
and noncancerous tissue by immunohistochemistry. In the 
80 paired tissue microarrays, eight paired cases were ex-
cluded owing to absent pathology for the PDAC tissue, and 
the remaining 72 paired cases were included for statistical 
analysis. In these cases of PDAC, COMT expression was 
moderate and mostly confined to the cellular cytoplasm 
(Figure 3A). In nonmalignant pancreatic tissue either adja-
cent to paired pancreatic cancer (72 cases) or paired benign 
pancreatic tumor (20 cases), we observed negative expres-
sion in the ductal epithelium (Figure 3B), moderate cyto-
plasmic expression of COMT in the pancreatic islet cells, 
and weak cytoplasmic expression of COMT in the acinar 
epithelium (Figure 3C).  
The staining intensity, percentage of positive cells and 
score were assessed according to the aforementioned crite-
ria. There were statistically significant differences between 
pancreatic cancer and nonmalignant pancreatic tissue in 
staining intensity of COMT (P=0.003), percentage of COMT 
positive cells (P<0.001) and score (P<0.001) by Chi-square 
test analysis or Fisher’s exact test. Mann-Whitney U-test 
revealed that the percentage of COMT positive cells and the 
score of PDAC were significantly higher than those of  
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Figure 3  Immunohistochemical analysis of COMT in PDAC and nonma-
lignant tissue. A, Moderate COMT expression in PDAC (original magnifi-
cation ×400). B, Negative expression of COMT in ductal epithelial cells as 
indicated by arrow (original magnification ×400). C, Weak COMT expres-
sion in nonmalignant pancreatic tissue and moderate expression of COMT  
in islet cells as indicated by asterisk (original magnification ×400). 
nonmalignant tissue were (P<0.001 and P<0.001, respec-
tively). 
2.4  Statistical analysis of COMT expression in PDAC 
with clinicopathologic parameters 
Samples were grouped as COMTHigh (immunohistochemical 
scoremedian immunohistochemical score=4) and as 
COMTLow (immunohistochemical score<median immuno-
histochemical score=4). Chi-square tests or Fisher’s exact 
tests revealed that clinicopathologic parameters, T (primary 
tumor) and TNM stages were significantly correlated with 
COMT expression status (P=0.017 and P=0.049, respec-
tively) as shown in Table 1. Using the Mann-Whitney 
U-test, we also found that patients with early T stages 
(T1/T2) displayed significantly higher expression of COMT 
than those with late T stages (T3/T4) (P=0.022). However, 
there were no significant differences between COMT ex-
pression in PDAC cases and other clinicopathologic param-
eters including the patients’ sex, age, N (regional lymph 
node), M (distant metastasis), pathological grade and nerve 
invasion (P>0.05). 
3  Discussion 
Estrogens are catabolized by hydroxylation reactions. 
17-Estradiol is metabolized by 16α-hydroxylation with the 
formation of catechol estrogens, 2-hydroxy- and 4-hydroxy-      
estrone/estradiol [16]. COMT catalyzes the process of 
methylation, which inactivates 16α-, 2-hydroxy-, and 4-    
hydroxy-compounds. 4-Hydroxyestrone and 16-hydroxy-      
estradiol have estrogenic properties and may be carcino-
genic [17,18]. In addition, previous studies demonstrated  
Table 1  Correlations between COMT expression pattern and clinico-
pathologic parametersa) 
Characteristics Cases (n) 
COMT expression (%) 
Low High P-value 
Sex    0.382 
Male 47 18(38) 29(62)  
Female 25 7(28) 18(72)  
Age    0.458 
58 median 36 11(31) 25(69)  
<58 median 36 14(39) 22(61)  
T    0.017* 
T1, T2 55 15(27) 40(73)  
T3, T4 17 10(59) 7(41)  
N    0.447 
N0 38 12(32) 26(68)  
N1 27 11(41) 16(59)  
M    0.296 
M0 66 23(35) 43(65)  
M1 3 2(67) 1(33)  
TNM    0.049* 
I 28 8(29) 20(71)  
II 29 11(38) 18(62)  
III, IV 6 5(83) 1(17)  
Histological grade    0.110 
MD 40 18(45) 22(55)  
PD 24 6(25) 18(75)  
Nerve invasion    0.083 
Yes 36 16(44) 20(56)  
No 36 9(25) 27(75)  
a) MD, moderately differentiated; PD, poorly differentiated; *, statisti-
cally significant (P<0.05). 
 
that 2-methoxyestrodiol (2-ME), a metabolite of 2-hydro-        
xyestradiol, may be a promising anti-angiogenic and anti-      
cancer agent [19]. The anti-proliferative action of 2-ME was 
specific for cancer cells and was mediated by the induction 
of programmed cell death or apoptosis [20]. In addition, an 
epidemiological study in Ontario, Canada, indicated that 
pancreatic cancer is, at least in part, an estrogen-dependent 
disease [21]. A population-based case-control study of 
women from the San Francisco Bay area revealed that age 
at menopause (45 years vs. <45 years) was associated with 
a 1.8-fold increased risk of pancreatic cancer [22]. These 
reports suggest that pancreatic cancer might be an estro-
gen-dependent cancer, and 2-ME may have an inhibitive 
role in pancreatic cancer.  
The results of the present study indicated that COMT 
was expressed in human pancreatic cancer cell lines at both 
the mRNA and protein levels, further supporting our previ-
ous findings [6,7]. A previous publication demonstrated that 
in the rat pancreas, bright COMT immunofluorescence was 
observed in the islet cells, and COMT immunoreactivity 
was present in insulin-producing -cells and somatosta-
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tin-producing D-cells [23]. Our data were in line with these 
findings as the normal pancreatic tissue COMT expression 
was more immunoreactive in islet cells than in acinar cells, 
but there was almost no immunoreactivity in ductal epithe-
lial cells. Therefore, it is possible that the high expression of 
COMT in islet cells compensates for the expression differ-
ence in COMT between PDAC and noncancerous tissue, 
which would result in the equivalent expression level of 
COMT mRNA and protein between PDAC and noncancer-
ous tissue.  
The present study examined the potential role of COMT 
in PDAC. Our data revealed a high level of COMT expres-
sion in the majority of PDAC compared with noncancerous 
pancreatic tissue, as determined by immunohistochemistry. 
Interestingly, an inverse correlation was found between 
COMT expression and pathological T stages, in that 
COMTLow expression correlated with late T stages while 
COMTHigh expression correlated with early T stages. These 
results indicated that T1/T2 stage tumors, which are limited 
to the pancreas, had higher levels of COMT than those of 
T3/T4 stage tumors, which invade the surrounding organs. 
This suggests that COMTHigh expression may be an early 
event in the development of PDAC. To date, the association 
between COMT expression and pancreatic cancer has rarely 
been reported and no clear relationship has been identified 
regarding the effect of COMT expression on PDAC. Fur-
thermore, the effect of estrogen on pancreatic cancer re-
mains controversial, based on several clinical trials [24–26]. 
However, pancreatic cancers showed significantly higher 
estrogen receptor (ER)- mRNA levels than ER-negative 
and ER-positive breast cancers, and lower ER- mRNA 
expression than ER-negative breast cancers [27]. In more 
advanced pancreatic cancers, ER- mRNA levels signifi-
cantly decreased and ER-α mRNA levels increased [27]. In 
addition, Konduri and Schwarz reported that pancreatic 
cancer cells expressed functional ERs, generally with a high 
ER-:ER- ratio. Estrogen at physiological concentrations 
predominantly promoted pancreatic cancer cell proliferation 
in vitro, and cell lines with higher ER-:ER- ratios tended 
to show greater responsiveness to ER-modulating agents 
[28]. Therefore, based on previous reports and the results of 
the present study, we propose a hypothesis that in the early 
stages of PDAC, the dominant expression of ER- in pan-
creatic cancer induces the activation of the estrogen meta-
bolic pathway and the high expression of COMT, which act 
as promoting factors for PDAC genesis and development. 
During the development of PDAC, ER- expression de-
creases and 2-ME increases, the generation of which is di-
rectly catalyzed by COMT. Thus, the expression of COMT 
is reduced either by a less active estrogen metabolic path-
way or by a negative feedback mechanism. However, addi-
tional studies are required to further elucidate the can-
cer-promoting mechanism of COMT.  
In summary, our study reveals for the first time that 
COMT is highly expressed in pancreatic cancer tissue and is 
significantly associated with early T stages (T1/T2). There-
fore, COMT might serve as a potential biomarker for ap-
plied clinical pathology in PDAC. 
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